MedTrace Logo

Preoperative Herceptin and Navelbine for Breast Cancer

NCT00148681 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2019-01-15

No results posted yet for this study

Summary

The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.

Conditions

Interventions

DRUG

Herceptin

Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)

DRUG

Navelbine

Intravenously every week for 12 weeks

DRUG

Doxorubicin

Every 3 weeks for 12 weeks

DRUG

Cyclophosphamide

Intravenously every 3 weeks for 12 weeks

DRUG

Paclitaxel

Weekly for 12 weeks (or a similar schedule)

Sponsors & Collaborators

Principal Investigators

  • Eric Winer, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2003-05-31
Completion
2003-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148681 on ClinicalTrials.gov